Physician profile
Andrew Antony
NPI 1104263862
$1,108.69
in general payments reported to CMS, 2019-2025
13 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $115 · 2021: $101 · 2022: $250 · 2023: $109 · 2024: $251 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.12 | 2020-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $236.05 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.68 | 2021-2024 | Xifaxan, Trulance |
| Lucid Diagnostics INC. | $124.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.77 | 2020-2021 | |
| Celgene Corporation | $35.56 | 2021 | |
| Gilead Sciences, INC. | $33.60 | 2022-2023 | |
| Micro-Tech Endoscopy USA, INC. | $23.61 | 2023-2024 | Lesion Hunter, Blueboost |
| Ironwood Pharmaceuticals, INC | $17.94 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $17.77 | 2020 | |
| Braintree Laboratories, INC. | $15.61 | 2020 | |
| Redhill Biopharma INC. | $10.99 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Antony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.